Field Trip Health & Wellness Ltd. (TSXV: FTHW) (the "Company"
or “Field Trip”), a global leader in the delivery of psychedelic
therapies, today announced that it has strengthened its leadership
team with the hiring of two senior executives.
The Company has appointed Stacey Hoisak as
Senior Vice President, General Counsel, and Dr. Monique Moller as
Vice President, Integrative Health.
Ronan Levy, Chairman & CEO, commented, “We
have deepened the expertise of the Field Trip leadership team with
these talented individuals as we head into this pivotal phase of
our growth plans. They bring unique perspectives and extensive
track records of working in innovative fields, which will be
invaluable as we scale Field Trip, by growing our digital
communities and expanding access to legal psychedelic-assisted
treatments. The addition of Stacey and Monique’s diverse skill sets
will effectively round out our executive team and support the
execution of our broadened, holistic approach to mental health and
wellbeing, which integrates medicine, technology, and community to
help people become free from depression and anxiety.”
Stacey Hoisak is an accomplished
corporate/securities lawyer and business leader, with more than 20
years of experience and extensive background in corporate
governance, commercial law, regulatory compliance, public and
private M&A, FinTech, and capital markets. Most recently, Ms.
Hoisak held the roles of Chief Executive Officer, Chief Legal
Officer, Chief Privacy Officer and Director of Coinsquare Ltd.
Previously, she held General Counsel and Corporate Secretary
positions at Birch Hill Equity Partners and Alpha Exchange, and was
Director of Regulatory Compliance for TMX Group and an associate in
Stikeman Elliott LLP’s corporate/securities group. Ms. Hoisak
studied at both the University of New Brunswick (B.Sc (Pre-Med) and
LL.B) and Osgoode Hall Law School (Masters in Securities Law).
Dr. Monique Moller is an esteemed physician with
expertise in mental health and addiction, and is passionate about
education, research, and clinical initiatives within the
psychedelic field. Dr. Moller previously served as staff physician
at the Centre for Addiction and Mental Health (CAMH) and the
Substance Use Service at Women’s College Hospital, and many
academic roles, including Deputy Program Director for the Enhanced
Skills Program in Addiction Medicine, Medical Elective Coordinator
for Addictions at CAMH, and the Addiction Lead for the Foundations
Curriculum in Undergraduate Medical Education at the University of
Toronto. Dr. Moller created the Addiction Consult Service at CAMH,
developing a robust clinical teaching unit in the process. Dr.
Moller holds faculty appointment at the University of Toronto as
Assistant Professor in the Division of Mental Health and Addiction,
Department of Family and Community Medicine as well as Pharmacology
& Toxicology, and also supports True North Medical, the largest
virtual Addiction Medicine program in the province of Ontario,
Canada.
Field Trip would also like to thank Paula Amy
Hewitt, who resigned as its Senior Vice President, General Counsel,
Chief Privacy Officer and Corporate Secretary for her many
contributions, hard work and dedication to the Company and its
predecessors. Paula’s innovative advice, strong leadership and
belief in the potential of psychedelics to improve the human
condition were essential to Field Trip’s growth to date. The
Company wishes Paula every success in her future endeavours.
In addition, the Company announced today that it
plans to release financial results for its fiscal 2023 second
quarter for the three-month period ended September 30, 2022, after
market close on Monday, November 28, 2022.
The Company will conduct a conference call and
webcast to discuss its results the following morning, Tuesday,
November 29, 2022 at 8:30 a.m. ET. To access the call, please dial
1-877-407-9716 (within the U.S.) or 1-201-493-6779 (outside the
U.S.) and provide conference ID 13734182. A live webcast of the
conference call can be accessed via the Events and Presentations
section of the Field Trip Health & Wellness Investor Relations
website here.
For those unable to attend the live call, a
telephonic replay will be available until 11:59 p.m. ET on Tuesday,
December 13, 2022. To access the replay dial 1-844-512-2921 (within
the U.S.) or 1-412-317-6671 (outside the U.S.) and provide
conference ID 13734182. The webcast will be archived and available
in the Events and Presentations section of the Field Trip Health
& Wellness Investor Relations website approximately one hour
after the conclusion of the live call.
About Field Trip Health & Wellness
Ltd.
With a large global community of
psychedelic-interested people, proprietary psychedelic therapies
generating transformative results for people in the treatment of
mental health conditions and a brand and share of voice that is
reaching millions of people, Field Trip is a center of gravity for
the psychedelic renaissance.
Learn more at https://www.meetfieldtrip.com,
https://www.fieldtriphealth.com and
https://www.fieldtriphealth.nl.
Follow us on Twitter and Instagram:
@fieldtriphealth.To receive company updates about Field Trip and to
be added to the email distribution list please sign up here.
Download Field Trip’s app here.
Cautionary Note Regarding
Forward-Looking Information
This release includes forward-looking
information (within the meaning of Canadian securities laws and
within the meaning of the United States Private Securities
Litigation Reform Act of 1995) regarding the Company and its
business. Often but not always, forward-looking information can be
identified by the use of words such as "expect", "intends",
"anticipated", "believes" or variations (including negative
variations) of such words and phrases, or state that certain
actions, events or results "may", "could", "would" or "will" be
taken, occur or be achieved. Such statements are based on the
current expectations and views of future events of the management
of the Company and are based on assumptions and subject to risks
and uncertainties. Although the management believes that the
assumptions underlying these statements are reasonable, they may
prove to be incorrect. The forward-looking events and circumstances
discussed in this release may not occur and could differ materially
as a result of known and unknown risk factors and uncertainties
affecting the companies, including ability of Field Trip to realize
its business plan, grow its clients base or app user base, uptake
in existing or new programs by clinicians or patients, if any,
results or ability to commercialize its research and cultivation
business or uptake in any products developed thereby, acceptance of
psychedelic treatments by clinicians, patients, and regulators,
ability or effect of any clinical restructuring, the ability of
Field Trip to realize on its business plan for broadened, holistic
approach to mental health and wellbeing and/or future changes in
regulatory regimes which govern Field Trip’s business. Although the
Company has attempted to identify important factors that could
cause actual actions, events or results to differ materially from
those described in forward-looking statements, there may be other
factors that cause actions, events or results to differ from those
anticipated, estimated or intended, including those risk factors
contained in the Company's public filings at www.sedar.com.
Accordingly, readers should not place undue reliance on any
forward-looking statements or information. No forward-looking
statement can be guaranteed. Except as required by applicable
securities laws, forward-looking statements speak only as of the
date on which they are made and the Company does not undertake any
obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events,
or otherwise. Additional information relating to the Company, can
be located on the SEDAR website at www.sedar.com.
Neither TSX Venture Exchange, or its Regulation
Services Provider, have approved the contents of this release or
accept responsibility for the adequacy or accuracy of this
release.
CONTACTS:
Field Trip Health &
Wellness:Ronan LevyChairman & CEO (416)
505-0929ronan@fieldtriphealth.com
Investor contacts:Phil Carlson
/ Sophia Bashford KCSA Strategic Communications(646) 573-0776
/ (929) 246-7307fieldtripIR@kcsa.com
Field Trip Health and We... (TSXV:FTHW)
Historical Stock Chart
From Mar 2024 to Apr 2024
Field Trip Health and We... (TSXV:FTHW)
Historical Stock Chart
From Apr 2023 to Apr 2024